EASYGEN is a collaborative EU project aiming to optimise hospital workflows of CAR-T cell therapy for a sustainable healthcare workforce.
About EASYGEN
Today’s licensed CAR-T therapies are typically manufactured in a handful of central GMP plants. In real-world cohorts, the median vein-to-vein time ranges between 4 and 6 weeks.
About 30%EASYGEN's (EASY workflow integration for GENe therapy) goal is to enable an automated, modular manufacturing platform for CAR-T cell production at the point-of-care.
Reduce treatment cost by 50%
Reduce manufacturing time significantly
Broaden eligibility for new European patient groups
Embed a platform seamlessly into routine hospital workflows
EASYGEN brings together 18 international partners from academia and industry, and is led by Fresenius SE & Co.KGaA and Fraunhofer IZI as academic co-lead.
